SCHEMBL7919604

SCHEMBL7919604

COc1cc2c(cc1[N+](=O)[O-])CCN(C)CC2c1ccccc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
DRD1 P21728 7/20 0.53
DRD5 P21918 4/20 0.51
SIRT6 Q8N6T7 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.41
THPO P40225 1/20 0.41
HIF1A Q16665 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MTOR P42345 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
KDM4E B2RXH2 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7919596 0.85 DRD1 (0.67) CYP3A4CYP2D6DRD1DRD5MEN1
SCHEMBL9405364 0.75 DRD1 (0.59) CYP3A4CYP2D6DRD1DRD5
SCHEMBL2574136 0.75 SIRT6 (0.57) DRD1DRD5SIRT6MEN1KMT2A
SCHEMBL9764189 0.75 DRD1 (0.59) CYP3A4CYP2D6DRD1DRD5MEN1
SCHEMBL7922430 0.74 DRD1 (0.55) CYP3A4CYP2D6DRD1DRD5MEN1
SCHEMBL9404237 0.73 CYP3A4 (0.39) CYP3A4CYP2D6DRD1DRD5CA1
SCHEMBL9839693 0.72 DRD1 (0.72) CYP3A4CYP2D6DRD1DRD5MEN1
SCHEMBL9839699 0.72 DRD1 (0.72) CYP3A4CYP2D6DRD1DRD5MEN1
Trepipam SCHEMBL11704977 0.71 CYP2D6 (1.00) CYP3A4CYP2D6DRD1DRD5MEN1
Trepipam SCHEMBL29374758 0.71 CYP2D6 (1.00) CYP3A4CYP2D6DRD1DRD5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6211173-B1 Use of 2,3,4,5-tetrahydro-1H-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders CENES LIMITED (GB) 2001-04-03 US disclosed
EP-1011679-A1 USE OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SLEEP DISORDERS CeNes Limited (GB) 2000-06-28 EP disclosed
WO-1998040072-A1 USE OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SLEEP DISORDERS CENES LIMITED (GB) 1998-09-17 WO disclosed
EP-0347672-B1 Benzazepine derivatives NOVO NORDISK AS (DK) 1994-03-02 EP disclosed
US-5025009-A Treatment of central nervous system disorders; bioavailability NOVO NORDISK A/S (DK) 1991-06-18 US disclosed
US-5010074-A Treating CNS disorders; dopamine antagonist; bioavailability NOVO NORDISK A/S (DK) 1991-04-23 US disclosed
EP-0347672-A1 Benzazepine derivatives NOVO NORDISK A/S (DK) 1989-12-27 EP disclosed